UNICYCIVE THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Amortization of Debt Discount (Premium) of $488.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2023-03-31
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $41.00K.
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2021-06-30 was $250.00K.
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2021-03-31 was $197.00K.
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2021 was $488.00K, a 162.37% increase from fiscal 2020.
- UNICYCIVE THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2020 was $186.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $41.00K derived: sum of 2 quarters · filed 2023-03-31 | $291.00K derived: sum of 3 quarters · filed 2023-03-31 | $488.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $291.00K derived: sum of 2 quarters · filed 2022-11-14 | $488.00K 10-Q · filed 2022-11-14 | $615.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $447.00K 10-Q · filed 2022-08-15 | $574.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $197.00K 10-Q · filed 2022-05-12 | $324.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $186.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $59.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |